Empowered Patient Podcast

Michael Demurjian is Chairman and CEO of Aspargo Labs, a drug development company focused on improving drug delivery through suspension-based formulation and smart device technology. Traditional pill-based drug delivery has significant limitations, with poor absorption rates and difficulties swallowing for many patients. The company's initial focus is on an oral spray formulation of sildenafil to treat erectile dysfunction that has shown rapid absorption. Suspension technology can be applied to reformulate many prescription and over-the-counter drugs to improve drug delivery, adherence, the onset of action, and user experience. Michael explains, "Here at Aspargo we have a proprietary technology, both in the suspension and in how we coat it, so that we can mask the taste of the drug itself. And so I know you're going to probably go down the path of our first drug to market, and I'll answer the next question, but masking is key because there are two things that happen with the masking. One is you make it more